ADVFN US – Market Content Editor
-

Stocks Climb as Anthropic IPO Filing Revives AI Trade Ahead of Fed Decision and Big Tech Earnings
Wall Street finished higher on Monday, with all three major averages posting gains as investors rebuilt confidence in artificial intelligence stocks after a choppy previous week. News that Anthropic filed to list on Nasdaq under the ticker ANT helped lift tech shares, while a pullback in oil prices eased some inflation worries. Traders also positioned…
-

MakeMyTrip Shares Rise 4.8% as Q2 Profit Improves Despite Revenue Missing Estimates
MakeMyTrip Limited (NASDAQ:MMYT) reported second-quarter fiscal 2027 financial results that met analysts’ earnings expectations but fell short of revenue forecasts, as growth in domestic travel demand and improved profitability offset lower international travel activity. The India-based online travel services provider reported adjusted earnings per share of $0.47, matching the analyst consensus estimate. Quarterly revenue increased…
-

Cemex Reports 12% Rise in Q3 Operating EBITDA to $990 Million, Shares Gain Nearly 3%
Cemex, S.A.B. de C.V. (NYSE:CX) reported third-quarter 2026 earnings and revenue above analysts’ expectations, supported by higher cement sales volumes in Mexico, pricing adjustments and lower operating costs in parts of its business. The Mexican building materials producer reported adjusted earnings of $0.28 per American Depositary Share (ADS), exceeding the analyst consensus estimate of $0.24.…
-

Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer’s Data Approach
Acumen Pharmaceuticals Inc. (NASDAQ:ABOS) reported third-quarter 2026 financial results that exceeded analysts’ expectations, with a smaller net loss compared with the same period last year and an updated timetable for its Alzheimer’s disease clinical development programme. The clinical-stage biopharmaceutical company’s shares increased 5.56% in pre-market trading on Monday following the announcement. Acumen reported an adjusted…
-

Elbit Systems Secures $200 Million in Airborne Defence Contracts in Asia-Pacific
Elbit Systems Ltd. (NASDAQ:ESLT) has secured contracts worth approximately $200 million from an undisclosed country in the Asia-Pacific region for airborne intelligence, surveillance, target acquisition and reconnaissance (ISTAR) systems and military training solutions. The Israeli defence technology company said the agreements will be executed over a period of up to five years and cover the…
-

Easterly Government Properties Reports Higher Q3 Revenue and Earnings, Raises 2026 Guidance
Easterly Government Properties Inc. (NYSE:DEA) reported third-quarter 2026 financial results above analysts’ expectations for both earnings and revenue, supported by its portfolio of properties leased primarily to US government agencies. The real estate investment trust (REIT) reported net income of $0.12 per diluted share, exceeding the analyst consensus estimate of $0.07. Adjusted earnings per share…
-

Bank of Hawaii Shares Fall 7.5% After Q3 Earnings Miss Estimates
Bank of Hawaii Corporation (NYSE:BOH) reported third-quarter 2026 adjusted earnings per share of $1.49, below analysts’ consensus estimate of $1.51, despite increases in net income, revenue and net interest income. The bank’s shares declined 7.51% in pre-market trading on Monday following the earnings announcement. Quarterly net income reached $64.3 million, representing an increase of 0.7%…
-

Alliance Resource Partners Reports Higher Q3 Earnings and Revenue, Updates 2026 Guidance
Alliance Resource Partners, L.P. (NASDAQ:ARLP) reported third-quarter 2026 earnings and revenue above analysts’ expectations, supported by increased contributions from its coal operations and oil and gas royalty business. The US energy partnership reported adjusted earnings of $1.08 per unit, compared with the analyst consensus estimate of $0.85. Quarterly revenue increased 5.5% year on year to…
-

Johnson & Johnson Reports Phase 1 Prostate Cancer Drug Results at ESMO 2026
Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The company reported tumour responses and reductions in prostate-specific antigen (PSA) levels among patients who had previously received multiple treatments for the…
